These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 16715942

  • 1. [In vitro antituberculous activity of ofloxacin and levofloxacin against multidrug-resistant tuberculosis and clinical outcomes].
    Tada A, Kawata N, Shibayama T, Takahashi S, Hirano A, Kimura G, Takeuchi M, Okada C, Soda R, Takahashi K.
    Kekkaku; 2006 Apr; 81(4):337-44. PubMed ID: 16715942
    [Abstract] [Full Text] [Related]

  • 2. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
    Pracharktam R, Angkananukool K, Vibhagool A.
    J Med Assoc Thai; 2001 Sep; 84(9):1241-5. PubMed ID: 11800295
    [Abstract] [Full Text] [Related]

  • 3. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.
    Grimaldo ER, Tupasi TE, Rivera AB, Quelapio MI, Cardaño RC, Derilo JO, Belen VA.
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):546-50. PubMed ID: 11409582
    [Abstract] [Full Text] [Related]

  • 4. [A preliminary study on the definition of resistant breakpoints of ofloxacin and levofloxacin for Mycobacterium tuberculosis].
    Huang XR, Gao WW, Zhang XX, Wang SM, Pan YX, Ma Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Feb; 27(2):84-8. PubMed ID: 14990180
    [Abstract] [Full Text] [Related]

  • 5. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S, Tada A, Nagare H.
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [Abstract] [Full Text] [Related]

  • 6. [Clinical evaluation of new quinolones as antituberculosis drugs].
    Kawahara S, Tada A, Nagare H.
    Kekkaku; 1999 Jan; 74(1):71-5. PubMed ID: 10067058
    [Abstract] [Full Text] [Related]

  • 7. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
    Casal M, Ruiz P, Herreras A.
    Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
    [Abstract] [Full Text] [Related]

  • 8. [Multidrug-resistant tuberculosis. 4. Treatment and prognosis of multidrug-resistant tuberculosis].
    Ogawara M, Sakatani M.
    Kekkaku; 1998 Nov; 73(11):673-7. PubMed ID: 9866930
    [Abstract] [Full Text] [Related]

  • 9. [Experimental study on the antituberculous activity of ofloxacins].
    Duan L, Liang G, Li H.
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Apr; 20(2):98-100. PubMed ID: 10072834
    [Abstract] [Full Text] [Related]

  • 10. [Antituberculosis effect of levofloxacin].
    Lu Y, Zhu L, Duan L.
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jan; 23(1):50-4. PubMed ID: 11778184
    [Abstract] [Full Text] [Related]

  • 11. [Polymerase chain reaction-single strand conformation polymorphism analysis combined with nucleic acid hybridization to detect ofloxacin-resistant Mycobacterium tuberculosis mutation selected in vitro].
    Zhang JY, Wang SM, Li CY, Tian M, Zhang XX, Zhao B, Li WM, Zhao YL, Qiu YQ, Ma Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Dec; 28(12):841-4. PubMed ID: 16409787
    [Abstract] [Full Text] [Related]

  • 12. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
    Nam HS, Koh WJ, Kwon OJ, Cho SN, Shim TS.
    Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
    [No Abstract] [Full Text] [Related]

  • 13. Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
    Berning SE, Cherry TA, Iseman MD.
    Clin Infect Dis; 2001 Feb 15; 32(4):643-6. PubMed ID: 11181130
    [Abstract] [Full Text] [Related]

  • 14. [Therapeutic effect of ofloxacin on intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patients. Chest DIsease Cooperative Study Unit of National Sanatoriums in Kinki District].
    Nakae I, Nakatani K, Inoue S, Takahasi K, Ikeda N, Matsumoto T, Ozawa S, Sakatani M, Kita N, Tanaka S.
    Kekkaku; 1991 Apr 15; 66(4):299-307. PubMed ID: 1904960
    [Abstract] [Full Text] [Related]

  • 15. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
    Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ.
    Int J Tuberc Lung Dis; 2004 Mar 15; 8(3):361-8. PubMed ID: 15139476
    [Abstract] [Full Text] [Related]

  • 16. Ofloxacin in multidrug resistant tuberculosis.
    Walwaikar PP, Morye VK, Gawde AS.
    J Indian Med Assoc; 2003 Mar 15; 101(3):210-2. PubMed ID: 14603981
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar 15; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ.
    Clin Infect Dis; 2008 Aug 15; 47(4):496-502. PubMed ID: 18611154
    [Abstract] [Full Text] [Related]

  • 20. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
    Kawahara S, Kamisaka K, Tada A, Nakada H, Mishima Y, Yoshimoto S, Matsuyama T, Kibata M, Nagare J.
    Kekkaku; 1991 Jun 15; 66(6):429-31. PubMed ID: 1942726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.